AR100291A2 - Composición catártica - Google Patents

Composición catártica

Info

Publication number
AR100291A2
AR100291A2 ARP130103006A ARP130103006A AR100291A2 AR 100291 A2 AR100291 A2 AR 100291A2 AR P130103006 A ARP130103006 A AR P130103006A AR P130103006 A ARP130103006 A AR P130103006A AR 100291 A2 AR100291 A2 AR 100291A2
Authority
AR
Argentina
Prior art keywords
formula
fatty acid
acid triglyceride
cathartic composition
bicyclic compound
Prior art date
Application number
ARP130103006A
Other languages
English (en)
Inventor
Ueno Ryuji
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR100291(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR100291A2 publication Critical patent/AR100291A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

Una suspensión o solución no acuosa que comprende un compuesto bicíclico representado por la fórmula (1), 13,14-dihidro-15-ceto-16,16-difluoro-prostaglandina E1, un compuesto el cual es un tautómero monocíclico de la fórmula (1), y un triglicérido de ácido graso, donde el triglicérido de ácido graso estabiliza la forma de dosificación en una relación de compuesto bicíclico a tautómero monocíclico de al menos 20:1.
ARP130103006A 2000-09-05 2013-08-26 Composición catártica AR100291A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition

Publications (1)

Publication Number Publication Date
AR100291A2 true AR100291A2 (es) 2016-09-28

Family

ID=24630250

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010104216A AR030609A1 (es) 2000-09-05 2001-09-05 Composicion catartica
ARP130103006A AR100291A2 (es) 2000-09-05 2013-08-26 Composición catártica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010104216A AR030609A1 (es) 2000-09-05 2001-09-05 Composicion catartica

Country Status (25)

Country Link
US (7) US6414016B1 (es)
EP (2) EP1315485B1 (es)
JP (3) JP2004508327A (es)
KR (2) KR100918223B1 (es)
CN (1) CN100335049C (es)
AR (2) AR030609A1 (es)
AT (1) ATE476975T1 (es)
AU (2) AU2001282615B2 (es)
BR (1) BRPI0114042B8 (es)
CA (1) CA2419741C (es)
CZ (1) CZ304740B6 (es)
DE (2) DE60131547T2 (es)
DK (2) DK1315485T3 (es)
ES (2) ES2347697T3 (es)
HU (1) HU229319B1 (es)
IL (2) IL154534A0 (es)
MX (1) MXPA03001959A (es)
NL (1) NL300757I1 (es)
NO (1) NO332701B1 (es)
NZ (1) NZ524401A (es)
PT (2) PT1315485E (es)
RU (1) RU2694361C3 (es)
TW (1) TWI305147B (es)
WO (1) WO2002020007A1 (es)
ZA (1) ZA200301673B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
WO2004037268A1 (en) * 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
JP4889219B2 (ja) * 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
US8337891B2 (en) 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
CN101048163A (zh) * 2004-09-02 2007-10-03 苏坎波公司 用于治疗胃肠道疾病的前列腺素衍生物
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CA2595898C (en) * 2005-01-27 2015-04-28 Sucampo Ag Method and composition for treating central nervous system disorders
DK1853271T3 (da) 2005-03-04 2011-01-24 Sucampo Ag Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5711442B2 (ja) * 2005-04-12 2015-04-30 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用
KR20140147142A (ko) 2006-01-24 2014-12-29 가부시키가이샤 아루떼꾸 우에노 바이-사이클릭 화합물을 함유하는 약학적 조성물 및 바이-사이클릭 화합물의 안정화 방법
JP4851467B2 (ja) * 2006-02-07 2012-01-11 株式会社アールテック・ウエノ プロスタグランジン誘導体の製造法
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
US8372425B2 (en) * 2008-10-31 2013-02-12 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament
CA2748607A1 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2750487A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
BR112012006069A8 (pt) * 2009-09-18 2017-10-10 Adolor Corp Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
WO2011054087A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
WO2011072383A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
WO2011091513A1 (en) 2010-01-28 2011-08-04 Apotex Pharmachem Inc. Polymorphic forms of lubiprostone
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
ES2735992T3 (es) 2013-04-12 2019-12-23 Ardelyx Inc Compuestos de unión a NHE3 y procedimientos para inhibir el transporte de fosfatos
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
AR105029A1 (es) * 2015-06-19 2017-08-30 Sucampo Ag Composición farmacéutica que comprende derivado de ácido graso
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CN110494721B (zh) * 2017-04-20 2022-06-24 株式会社岛津制作所 分光光度计
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (es) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
EP0310305B1 (en) 1987-10-02 1992-07-22 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Cathartics
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
DK1062952T3 (da) * 1998-03-11 2003-11-24 Grelan Pharmaceutical Co Brusende enteropræparater
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
ATE308606T1 (de) * 2000-07-14 2005-11-15 Henkel Kgaa Kompartiment-hohlkörper enthaltend wasch-, reinigungs- oder spülmittelportion
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
PT1857105E (pt) 2010-10-08
JP2004508327A (ja) 2004-03-18
HUP0302422A2 (hu) 2003-10-28
WO2002020007A1 (en) 2002-03-14
ES2347697T3 (es) 2010-11-03
DE60131547D1 (de) 2008-01-03
RU2694361C3 (ru) 2020-07-20
ZA200301673B (en) 2003-11-26
RU2694361C9 (ru) 2019-12-25
CN100335049C (zh) 2007-09-05
US6414016B1 (en) 2002-07-02
US20140235665A1 (en) 2014-08-21
US20030040528A1 (en) 2003-02-27
KR100901102B1 (ko) 2009-06-08
NO20030996L (no) 2003-05-02
CA2419741A1 (en) 2002-03-14
US20120022152A1 (en) 2012-01-26
DE60142810D1 (de) 2010-09-23
HU229319B1 (en) 2013-10-28
CN1655776A (zh) 2005-08-17
EP1315485A1 (en) 2003-06-04
US20050222195A1 (en) 2005-10-06
US6610732B2 (en) 2003-08-26
AU8261501A (en) 2002-03-22
NL300757I2 (es) 2015-12-29
BR0114042A (pt) 2003-07-22
DE60131547T2 (de) 2008-10-23
JP2009286806A (ja) 2009-12-10
BRPI0114042B1 (pt) 2016-11-08
CZ304740B6 (cs) 2014-09-17
ES2296786T3 (es) 2008-05-01
HUP0302422A3 (en) 2005-02-28
EP1857105A2 (en) 2007-11-21
DK1315485T3 (da) 2008-03-03
AR030609A1 (es) 2003-08-27
DK1857105T3 (da) 2010-09-20
JP2009114217A (ja) 2009-05-28
CA2419741C (en) 2010-11-30
TWI305147B (en) 2009-01-11
NO20030996D0 (no) 2003-03-04
US20120237598A1 (en) 2012-09-20
JP4684334B2 (ja) 2011-05-18
KR20080091278A (ko) 2008-10-09
US8114890B1 (en) 2012-02-14
US8071613B2 (en) 2011-12-06
BRPI0114042B8 (pt) 2021-05-25
NO332701B1 (no) 2012-12-10
AU2001282615B2 (en) 2006-06-22
KR100918223B1 (ko) 2009-09-21
RU2694361C2 (ru) 2019-07-12
IL154534A0 (en) 2003-09-17
NL300757I1 (es) 2015-12-29
EP1315485B1 (en) 2007-11-21
US20030216465A1 (en) 2003-11-20
US8748454B2 (en) 2014-06-10
PT1315485E (pt) 2008-01-23
IL154534A (en) 2010-04-29
EP1857105A3 (en) 2008-03-05
KR20030029919A (ko) 2003-04-16
EP1857105B1 (en) 2010-08-11
NZ524401A (en) 2004-08-27
ATE476975T1 (de) 2010-08-15
MXPA03001959A (es) 2003-06-24

Similar Documents

Publication Publication Date Title
AR100291A2 (es) Composición catártica
ATE292460T1 (de) Zusammenstellungen die aktive stilbenoidverbindungen enthalten zur senkung des triglyceridspiegels
UY27320A1 (es) Nuevas composiciones farmacéuticas
CO5251404A1 (es) Compuestos antibioticos de azalida
JP2003520232A5 (es)
AR109354A2 (es) Una composición que comprende un compuesto bicíclico y compuesto
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
DE69922824D1 (de) Seifenstücke mit wenig oder keinem synthetischen tensid
BR0112812A (pt) Titanato de potássio e magnésio lepidocrocìtico, método para fabricar o mesmo e material de fricção
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
DE60110438D1 (de) Zusammensetzungen enthaltend stilbenoide mit einer hypoglykämischen wirkung
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
BR0010242A (pt) Composições quìmicas que atraem artrópodes
ES2194929T3 (es) Composiciones de precursor de blanqueo de tipo peroxiacido hidrofobo estabilizadas con un acido carboxilico soluble en agua.
AR059764A2 (es) Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
EA199900301A2 (ru) Замещенные трициклические соединения
MXPA04000634A (es) Barra de detergente mejorada y un proceso para fabricacion.
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
PT1125907E (pt) Intermediarios para a producao de citalopram
NO20025054L (no) Oksidasjonsprosess for fremstilling av mellomproduktet 6.alfa., 9.alfa.-difluor-11.beta., 17.alfa.-dihydroksy-16.alfa.-metyl-androst-1,4-dien-3-on 17.beta.-karboksylsyre
AR063894A1 (es) Uso de un acido indazolmetoxialcanoico para preparar una composicion farmaceutica

Legal Events

Date Code Title Description
FC Refusal